



**Minutes of the Meeting of the Sheffield Area Prescribing Group
 19th March 2026 via MS Teams**

Attendee present:	Time of attendance: (if not full meeting)	Attendee name & initials:	Attendee title, organisation, and role (where applicable)
Yes		Dr Andrew McGinty - AMc	GP, NHS SY ICB, and joint Chair of APG
No		Dr Zak McMurray - ZM	Medical Director NHS SY ICB and joint Chair of APG
Yes		Heidi Taylor - HT	Programme Director for Medicines Optimisation (Clinical Effectiveness, Quality and Safety) NHS SY ICB
Yes		Hilde Storkes - HS	Lead Pharmacist (Formulary), MO Strategy & Delivery (Sheffield) NHS SY ICB
No		Abiola Allinson - AA	Chief Pharmacist. Sheffield Healthcare Partnership University NHS Trust (SHPU)
No		Dr Jonathan Mitchell - JM	Consultant representative. Sheffield Healthcare Partnership University NHS Trust (SHPU)
No		Joanne Wragg - JW	Chief Pharmacist, Sheffield Children's FT
Yes		Andrew Moore - AM	Pharmacoeconomics Pharmacist, STHFT. Deputising for STHFT Chief Pharmacist.
Yes		Dr Laura Smy - LS	GP, NHS South Yorkshire ICB and Representative of Local Medical Committee (LMC).
Yes		Dr Rhona Leadbetter - RL	GP, NHS South Yorkshire ICB
Yes		Dr Trish Edney - TE	Lay member. Healthwatch representative
Yes		Dr Craig Lawton - CL	GP, NHS South Yorkshire ICB
No		Mr Veeraraghavan Chidambaram-Nathan - VN	Consultant representative STHFT
Yes		Chris Bland - CB	Community Pharmacy South Yorkshire representative.
No		Shameila Afsar-Baig - SA	Senior Pharmacist, MO Strategy & Delivery (Sheffield) NHS SY ICB
Yes		Claire Stanley - CS	Senior Pharmacist, MO Strategy & Delivery (Sheffield) NHS SY ICB
Yes		Jenni Bussey - JB	Lead MO Pharmacy Technician (Clinical Effectiveness) NHS SY ICB, and APG Professional Secretary
Yes	13:30-13:40	Helen Taylor - HelTay	Pharmacist, MO Strategy & Delivery (Sheffield) NHS SY ICB - attended re: palliative care formulary update (section 9)
Yes	13:30-13:40	Dr James Davies - JD	Lead Palliative Care Consultant, STHFT – attended re: palliative care formulary update (section 9)
Yes	13:30-13:40	Amy Muscroft - AMu	Principal Palliative Care Pharmacist, St Luke's Hospice – attended re: palliative care formulary update (section 9)

Summary Points and Recommendations from March 2026

APG approvals	<ul style="list-style-type: none"> Updated Sheffield Palliative Care formulary Updated Endocrine section of Sheffield formulary chapter 6
IMOC approvals	<ul style="list-style-type: none"> Daridorexant prescribing information & patient information leaflet is now live on the MO website. The SY TLDL has also been updated to Green. Prescribing Guidelines For The Use Of SGLT2 Inhibitors (Dapagliflozin And Empagliflozin) In The Management Of Chronic Heart Failure- Now live on the MO website- These recommendations are an update and will replace the AMBER-G guidance for SGLT2 inhibitors (dapagliflozin and empagliflozin)

	<p>in heart failure (Barnsley Area Prescribing Committee, 2024) and the Sheffield guidance for primary care use of dapagliflozin and empagliflozin in heart failure with reduced ejection fraction (HFrEF) in patients with and without diabetes mellitus (Iqbal, 2023). SY TLDL has been updated to reflect the change in traffic light status to green</p> <ul style="list-style-type: none"> • South Yorkshire Guideline on Emollients and risk of severe and fatal burns- updated (links updated) • Tirzepatide (Type 2 Diabetes) guidance - updated document to previously approved guideline - Now live on the MO website • MDS (Monitored Dosage Systems) – Patient Information Leaflet- was approved but required some amendments. Still to have final sign off from chair. • Review Period for IMOC Documents- agreed move to 5-year review cycle - with interim updates triggered by NICE/safety events. 	
IMOC SY TLDL approvals	<ul style="list-style-type: none"> • Appendix 1 – March updates 	
		ACTION
1.	Welcome, Apologies for Absence & Quoracy	
	<p>Apologies from SA, JW, AA & VCN were received in advance of the meeting. The chair declared the meeting to be quorate.</p> <p>Presenting attendees: Helen Taylor – Lead Pharmacist, MOT, SY ICB Amy Muscroft - Principal Palliative Care Pharmacist, St Luke's Hospice & Dr James Davies, Lead Palliative Care Consultant, STHFT attending (to present palliative care formulary update - section 9)</p>	
2.	Declarations of Interest	
	<p>No new declarations of interest were made; existing declarations were deemed as not relevant to the agenda for this meeting for core members.</p>	
3.	Draft minutes of the February 2026 APG meeting	
	<p>The draft minutes were approved as an accurate representation of the February meeting.</p>	
4.	Matters Arising from the February 2026 APG meeting	
	<ul style="list-style-type: none"> • GF position statement (now on SY website as per below) • Query on tamoxifen impact on primary care workload • Vitamin B12 guidance amendments virtually approved • PILs for co-codamol MSN • Daridorexant pathway query • Feedback to LMC re: prometrium in sensitive cohort <p>Due to the adjustment in meeting timings in relation to the ICB's last-minute organisational change webinar, the above matters arising were not addressed other than to ask for comment from members by exception. Any outstanding matters can be addressed at a future meeting & have been added to the forward planner by the secretary.</p>	<p>SA/JB SA AMc/SA/RL HelTay SA LS</p> <p>JB</p>

5.	Papers on MO website	
	<p>South Yorkshire:</p> <ul style="list-style-type: none"> • Daridorexant prescribing information & patient information leaflet • Prescribing Guidelines for the use of SGLT2 Inhibitors (Dapagliflozin and Empagliflozin) in the management of Chronic Heart Failure • South Yorkshire Guideline on Emollients and risk of severe and fatal burns- updated (links updated) • Tirzepatide (Type 2 Diabetes) guidance - updated document to previously approved guideline • SY Gluten Free Prescribing position statement • updated Shared Care Protocol for Denosumab 60mg/ml injection • 3rd party ordering patient leaflet <p>Sheffield</p> <ul style="list-style-type: none"> • March 2026 TLDL updated re: IMOC TLDL approvals • Vitamin B12 guidance • Ratified minutes from February’s APG added 20/03/2026 (post meeting note) 	
6.	Virtual Proposals agreed under delegated authority	
	None for this meeting.	
7.	Medicines Safety Update	
	In the absence of SA, the February safety report details and associated actions were addressed by exception where a member required more information. If any members have any queries/feedback they were asked to email these to SA as required.	ALL
8.	Pharmacy and Prescribing Commissioning Group Feedback (PPCG)	
	AMc informed that there was nothing to report as there has not been a meeting held since January 2026.	
9.	Protocols/Prescribing Guidelines/TLDL applications pre-IMOC	
	<p>Due to aforementioned time constraints, the two papers that needed to be approved were brought forward to the beginning of the meetings and addressed first. The palliative care formulary was presented first as the authors of this document were external attendees solely for this paper.</p> <ul style="list-style-type: none"> • Sheffield Palliative Care Formulary update – Dr James Davies Lead Palliative Care Consultant at Sheffield Teaching Hospitals Foundation Trust (STHFT), Amy Muscroft Principle Palliative Care Pharmacist, St Luke’s Hospice & Helen Taylor Pharmacist, MO Strategy & Delivery (Sheffield) NHS SY ICB presented the updates to the formulary document and sought approval from the group. <p>Comments from the group thanked the authors for their hard work in updating what is quite a lengthy document.</p> <p>Some formatting issues were identified, and HS will forward her annotated version of the document to the authors to address these.</p> <p>RL also suggested consistency in annotating red drugs with specific telephone symbol, this will be addressed by the authors and agreed as being a sensible approach.</p> <p>Decision: subject to the above minor amendments, the group approved the updated palliative care formulary.</p> <p>Post meeting note: the secretary may have left the organisation by the time the final draft is made available for uploading to the MO website & saving in the meeting folders. Alternative arrangements for completing these tasks will need to be sought.</p>	

	<ul style="list-style-type: none"> • Sheffield formulary chapter 6 update (Endocrine section) – HS outlined the updates made to the chapter in relation to dydrogesterone being added as an additional option in addition to micronised progesterone. CL asked for consistency in the chapter updates as both ‘micronised progesterone’ and ‘progesterone micronised ‘ had been used. It was suggested that ‘progesterone micronised ‘ would be the preferred term as this is how it is referred to on the clinical system (EMIS web) in practice. HS will look into how it is written on SystmOne and take the most used term as the one used in the formulary chapter. <p>Decision: subject to the above minor amendments, the group approved the updated chapter 6 formulary.</p> <p>Post meeting note: the secretary may have left the organisation by the time the final draft is made available for uploading to the MO website & saving in the meeting folders. Alternative arrangements for completing these tasks will need to be sought.</p>	HS
10.	Integrated Medicines Optimisation Committee (IMOC)	
	<p>SA was unable to attend today’s APG meeting, the following information was shared via the agenda to highlight important information from the March IMOC meeting:</p> <p>Traffic Light Drugs List: From March ’26</p> <ul style="list-style-type: none"> • Dapagliflozin 10mg and Empagliflozin 10mg GREEN for the management of patients with heart failure with reduced, mildly reduced and preserved ejection fraction. Previously traffic lighted as Amber G • Numerous antihistamines as GREEN (see attachment) • Acetic acid 2% GREEN for acute otitis externa • Adapalene plus benzoyl peroxide 0.1%/2.5%. GREEN for acne • Alpha Tocopheryl (Vitamin E) AMBER G, as per BNF • Alprostadil cream AMBER G for Erectile dysfunction <p>Horizon Scanning document: from March ’26</p> <ul style="list-style-type: none"> • Methylphenidate (new MR chewable tablet formulation) AMBER for ADHD in children <p>Guidance approved:</p> <ul style="list-style-type: none"> • Daridorexant prescribing information & patient information leaflet is now live on the MO website. The SY TLDL has also been updated to Green. • Prescribing Guidelines For The Use Of SGLT2 Inhibitors (Dapagliflozin And Empagliflozin) In The Management Of Chronic Heart Failure- Now live on the MO website- These recommendations are an update and will replace the AMBER-G guidance for SGLT2 inhibitors (dapagliflozin and empagliflozin) in heart failure (Barnsley Area Prescribing Committee, 2024) and the Sheffield guidance for primary care use of dapagliflozin and empagliflozin in heart failure with reduced ejection fraction (HFrEF) in patients with and without diabetes mellitus (Iqbal, 2023). SY TLDL has been updated to reflect the change in traffic light status to green • South Yorkshire Guideline on Emollients and risk of severe and fatal burns- updated (links updated) • Tirzepatide (Type 2 Diabetes) guidance - updated document to previously approved guideline - Now live on the MO website • MDS (Monitored Dosage Systems) – Patient Information Leaflet- was approved but required some amendments. Still to have final sign off from chair. • Review Period for IMOC Documents- agreed move to 5-year review cycle - with interim updates triggered by NICE/safety events. 	

	<p>Stock shortages:</p> <ul style="list-style-type: none"> • Fluoxetine 20 mg Capsules (info sent via practice bulletin) • Fluorouracil (FU) Cream-Both branded and generic formulations affected locally. Issue for Bowen's disease management if alternatives are outside TLDL status. Chris Bland to check and inform Joy Power if required as could affect the AK guidelines. • Co-codamol 30/500 shortages- Opportunity for deprescribing and/or opioid reduction. 	
11.	NICE Guidance	
	<p>March TA document - In the absence of SA the following information was shared on the agenda:</p> <p>Major update to Type 2 Diabetes guideline; significant system work required. Immediate recommendation: ensure slow-release metformin is on all place-based formularies.</p> <p>Remaining items are RED/GREY.</p> <p>HT asked of anyone else had seen/attended recent training put on by NICE via a new organisation. She posed the question that this may be a newly adopted method of getting a more widespread audience to attend training sessions? Noone else in the group had seen this or attended.</p>	
12.	APG Mailbox.	
	Nothing for this meeting	
13.	Reports from Neighbouring Committees	
	Nothing was raised from this information from this meeting.	
14.	Never Events and Patient Safety Incidents.	
	Nothing reported	
15.	Any Other Business	
	<p>The chair acknowledged the addition of a farewell from the secretary to this section; JB was thanked for all her work keeping the meeting organised over the last two years since she stepped into the role and informed that she would be very much missed. All the members echoed this sentiment.</p> <p>HT also thanked the secretary for her contributions to the running of APG and also informed the group that HS will also be leaving the ICB under voluntary redundancy but not until the end of April. Her valued input into all the papers and documents that have gone through both FSG & APG was acknowledged. Both her and JB were thanked for everything they had contributed over many years in the Medicines Optimisation Team and wished all the best for their future endeavours.</p> <p>Post meeting note: Patient-safety concern: unreasonable requests for same-day warfarin MDS supply (Sheffield) – this was not addressed at the meeting due to time constraints and therefore has been added to the forward planner for the next meeting.</p>	CB

	The chair will send an email to the group members as a round-up to the shortened meeting timeframe to encourage comments on IMOC/safety papers etc. and to inform on ICB organisational updates as they become available.	
16.	<p>Date of the next meeting: The April meeting is likely to be stood down due to ICB organisational change. More information will follow from the chair when it becomes available.</p> <p>Post meeting note: Next meeting planned for 21st May 2026 13:30-15:00</p>	

Appendix 1 – March 2026 SY TLDL updates

Drug/Product Traffic Light Status	Brand name	Rationale / criteria	Indication	Date Considered	Comments	Agenda Item
Acoramidis (<i>new medicine</i>)	Beyontra®	1,6	Treatment of wild-type or variant transthyretin amyloidosis in adults with cardiomyopathy	Mar-26	<i>already classified Red with NCIE Tas at Feb 26 IMOC</i>	Horizon Scanning
Methylphenidate (<i>new MR chewable tablet formulation</i>) (AMBER)		1,23	Use as part of a comprehensive treatment programme for attention deficit/ hyperactivity disorder in children and adolescents aged 6 to 17 years when remedial measures alone prove insufficient	Mar-26	<i>Methylphenidate is already classified Amber on SY TLDL (Feb 24) at chemical substance level</i>	Horizon Scanning
Acetic acid 2%				Mar-26		IMOC subgroup TLDL
Adapalene plus benzoyl peroxide 0.1%/2.5%			acne	Mar-26		IMOC subgroup TLDL
Alpha Tocopheryl (Vitamin E) (AMBER G)			Following British National Formulary (BNF) advice	Mar-26	Alpha-Tocopheryl BNF Information	IMOC subgroup TLDL
Alprostadil cream (AMBER G)				Mar-26		IMOC subgroup TLDL
Bilastine			Antihistamine	Mar-26	Refer to Place based formularies/guidelines for alternative listing	IMOC subgroup TLDL
Loratadine			Antihistamine	Mar-26	Refer to Place based formularies/guidelines for alternative listing	IMOC subgroup TLDL
Cetirizine			Antihistamine	Mar-26	Refer to Place based formularies/guidelines for alternative listing	IMOC subgroup TLDL
Chlorphenamine			Antihistamine	Mar-26	Refer to Place based formularies/guidelines for alternative listing	IMOC subgroup TLDL
Hydroxyzine			Antihistamine	Mar-26	Refer to Place based formularies/guidelines for alternative listing	IMOC subgroup TLDL
Promethazine			Antihistamine	Mar-26	Refer to Place based formularies/guidelines for alternative listing	IMOC subgroup TLDL

Voxelotor			Treating haemolytic anaemia caused by sickle cell disease	Mar-26	remove from SY TLDL as product has been discontinued	IMOC subgroup TLDL
Fluoxetine 10mg tablets		4	cross reference to green traffic light entry	Mar-26		IMOC subgroup TLDL
Fluoxetine 10mg capsules			Fluoxetine 10mg capsules for cost-effective prescribing it is recommended that for patients requiring a 10mg dose, half a 20mg dispersible tablet or the 20mg/5ml oral solution are prescribed. For patients requiring a 30mg dose, patients should be dose optimised & prescribed as 30mg capsules	Mar-26	Update to Green(previously Grey) as capsules are more cost effective than tablets 10mg tablets ~£60 per box; capsules ~£2.	IMOC subgroup TLDL
Ganciclovir eye drops		1,6	All licensed indications	Mar-26	-	IMOC subgroup TLDL
Ketamine		1,6	All licensed indications	Mar-26	-	IMOC subgroup TLDL
Lanreotide		1,6	All licensed indications	Mar-26		IMOC subgroup TLDL
Levofloxacin		1,6	All licensed indications	Mar-26		IMOC subgroup TLDL
Dysopyramide		1,6	All licensed indications	Mar-26		IMOC subgroup TLDL
Budesonide M/R 4mg capsules	Kinpeygo	1,6	Targeted-release budesonide for treating primary IgA nephropathy Already traffic lighted update with new NICE TA1128	Mar-26	NICE TA 1128	NICE TA
Nivolumab		1,6	Nivolumab with chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancer Already Traffic Lighted	Mar-26	NICE TA1127	NICE TA
Niraparib		1,6	Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy	Mar-26	NICE TA1129	NICE TA
Talazoparib		1,6	Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer	Mar-26	NICE TA1130	NICE TA
Obinutuzumab		1,6	Obinutuzumab with mycophenolate mofetil for treating lupus nephritis Already traffic lighted	Mar-26	NICE TA1131	NICE TA
Belantamab mafodotin		1,6	Belantamab mafodotin with pomalidomide and dexamethasone for previously treated multiple myeloma Already traffic lighted	Mar-26	NICE TA1133	NICE TA
Dupilumab		1,6	Dupilumab for treating severe chronic rhinosinusitis with nasal polyps	Mar-26	NICE TA1134	NICE TA
Cerliponase alfa		7	Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2	Mar-26	HST34	NICE TA

Ruxolitinib		7	Ruxolitinib for treating moderate to severe chronic graft versus host disease after an allogeneic stem cell transplant in people 28 days to 17 years (terminated appraisal) Traffic Lighted Red for positive NICE TA's	Mar-26	NICE TA1132	NICE TA
Baloxavir marboxil		7	Baloxavir marboxil for treating and preventing influenza in children 1 to 11 years (terminated appraisal)	Mar-26	NICE TA1135	NICE TA
Dapagliflozin 10mg				Mar-26	-	IMOC Application
Empagliflozin 10mg	Jardiance®		The management of patients with heart failure with reduced, mildly reduced and preserved ejection fraction Previously traffic lighted as Amber G	Mar-26	-	IMOC Application